Also known as: TRAMP, Apo-3, TRAIL Receptor family, Tyrosine-rich acidic matrix protein
RUO: For Research Use Only
Staining of human TRAMP transfected cells with Anti-Human DR3 PE. Appropriate isotype controls were used (open histogram). Total viable cells were used for analysis.
Flow Cytometry Product Notes: Test Sizes: To accommodate multicolor flow cytometry, eBioscience is in the process of reducing test size volumes from 20 µL to 5 µL. Please check your antibody vial for the recommended test size. Fluorochrome Replacements: eBioscience is in the process of replacing all Alexa Fluor® 647 conjugated products with eFluor® 660 conjugated products.
Description
The JD3 monoclonal antibody reacts with human DR3, also known as Apo-3, WSL-1, TRAMP, LARD, DDR3, and TR3. DR3, a novel death receptor is expressed at low level by monocytes and granulocytes. Interaction of DR3 with its ligand activates NF-κB pathway and induces apoptosis. Initially, DR3 was thought to be a receptor for TWEAK, but further studies have shown that TWEAK could induce apoptosis via receptors distinct from DR3. JD3 has been reported for use in flow cytometric analysis.
Applications Reported
The JD3 antibody has been reported for use in flow cytometric analysis.
Applications Tested
The JD3 antibody has been tested by flow cytometric analysis of human peripheral leukocytes and human DR3-transfected cells. This can be used at less than or equal to 1 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 105 to 108 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest.
References
Nakayama, M., K. Ishidoh, et al. 2002. Multiple pathways of TWEAK-induced cell death. J Immunol 168(2): 734-43. Nakayama, M., N. Kayagaki, et al. (2000). "Involvement of TWEAK in Interferon {gamma}-stimulated Monocyte Cytotoxicity." J. Exp. Med. 192(9): 1373-1380.